// App-Quantinova.ai

AB0344 (2022) : EFFICACY OF SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) COMPARED WITH INTRAVENOUS INFLIXIMAB IN RHEUMATOID ARTHRITIS: A POST-HOC ANALYSIS OF A PHASE 3 RANDOMIZED CONTROLLED TRIAL

Researchers

Presenter

  • A. Constantin

Principal Investigators

  • R. Caporali

  • C. J. Edwards

  • J. E. Fonseca

  • F. Iannone

  • E. Keystone

  • H. Schulze-Koops

  • T. Kwon

  • S. Kim

  • S. Yoon

  • D. H. Kim

  • G. Park

  • D. Yoo

Medical Centers

  • Purpan University Hospital and University Toulouse III – Paul Sabatier, Rheumatology Department, Montpellier, France

  • University of Milan, Department of Clinical Sciences and Community Health, Research Center for Adult and Pediatric Rheumatic Diseases, Milan, Italy

  • University Hospital Southampton, Musculoskeletal Research Unit, NIHR Clinical Research Facility, Southampton, United Kingdom

  • Centro Hospitalar Universitário Lisboa Norte and, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Rheumatology Department, Lisbon, Portugal

  • Università Degli Studi Di Bari Aldo Moro, Rheumatology Unit, Department of Emergency and Organ Transplantation, Bari, Italy

  • University of Toronto, Rheumatology, Toronto, Canada

  • University of Munich, Department of Internal Medicine IV, Division of Rheumatology and Clinical Immunology, Munich, Germany

  • Celltrion Healtcare, Medical and Marketing Division, Incheon, Korea, Rep. of (South Korea)

  • Hanyang University Hospital for Rheumatic Diseases, Hanyang University Institute for Rheumatology Research, Department of Rheumatology, Seoul, Korea, Rep. of (South Korea)

Locations

  • France

  • Italy

  • United Kingdom

  • Portugal

  • Canada

  • Germany

  • Republic of South Korea

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • C reactive protein

  • Estrogen receptor alpha

  • Albumin/creatinine

Drug/Treatment

  • Infliximab

  • Infliximab Biosimilar

Outcome

  • N/A

Study Design

  • Randomized

  • Controlled

Phase

  • III

Study Id's

  • NCT03147248

Sponsors

  • Celltrion Healthcare

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved